Seven Eight Capital, LP Crinetics Pharmaceuticals, Inc. Transaction History
Seven Eight Capital, LP
- $918 Million
- Q2 2024
A detailed history of Seven Eight Capital, LP transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Seven Eight Capital, LP holds 8,150 shares of CRNX stock, worth $430,075. This represents 0.04% of its overall portfolio holdings.
Number of Shares
8,150
Previous 20,510
60.26%
Holding current value
$430,075
Previous $960,000
61.98%
% of portfolio
0.04%
Previous 0.1%
Shares
3 transactions
Others Institutions Holding CRNX
# of Institutions
243Shares Held
78.1MCall Options Held
268KPut Options Held
197K-
Black Rock Inc. New York, NY6.23MShares$329 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.11MShares$323 Million2.95% of portfolio
-
Wellington Management Group LLP Boston, MA4.62MShares$244 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$238 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.41MShares$233 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.84B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...